Nuvation Bio Inc.

This study tests an experimental drug called AB-106 in 173 adults with advanced non-small cell lung cancer that has a specific genetic change (ROS1 fusion). The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive AB-106 alone, and thei…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …